newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

100% Survival Rate in Anthrax-infected Rabbits Treated with OmadacyclineTotal Revenue Recognition to Paratek of $38.1 Million BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)